Tyrosinase is a key enzyme in melanogenesis and a target for the development of agents against hyperpigmentation. In this study, fifteen thiazolidine-2,4-dione derivatives conjugated with aryl- or benzylpiperazine moieties were designed and synthesized using a molecular hybridization strategy. Their inhibitory activity against mushroom tyrosinase was evaluated together with molecular docking, and selected compounds were further tested in SK-MEL-31 human melanoma cells and wild-type AB/TU zebrafish embryos. Ten derivatives inhibited mushroom tyrosinase more potently than kojic acid. Linker length and aromatic substitution strongly influenced activity, with TDP10 and TDP2 showing the highest potency (IC50 = 0.41 and 0.79 μM, respectively). Kinetic studies revealed inhibition profiles consistent with a non-competitive mechanism for both compounds. The selected derivatives reduced α-MSH-induced intracellular tyrosinase activity at 50 μM, with TDP7 producing the greatest effect. In zebrafish embryos, TDP2, TDP7, and TDP10 reduced pigmentation to different extents, with TDP7 showing a marked effect at 100 μM. Developmental toxicity assessment revealed concentration-dependent adverse effects at 100 μM, particularly for TDP10, whereas no adverse endpoints were observed at lower concentrations. These findings identify the thiazolidine-2,4-dione-aryl/benzylpiperazine scaffold as a promising starting point for the development of new tyrosinase inhibitors, while highlighting the importance of further efficacy and safety evaluation.
Thiazolidine-2,4-dione Conjugated with Aryl/Benzyl Piperazines: Design, Synthesis, Tyrosinase Inhibitory Activity, and In Vitro and In Vivo Anti-Melanogenic Effects
Romagnoli, Romeo
;De Ventura, TizianoFormal Analysis
;
2026
Abstract
Tyrosinase is a key enzyme in melanogenesis and a target for the development of agents against hyperpigmentation. In this study, fifteen thiazolidine-2,4-dione derivatives conjugated with aryl- or benzylpiperazine moieties were designed and synthesized using a molecular hybridization strategy. Their inhibitory activity against mushroom tyrosinase was evaluated together with molecular docking, and selected compounds were further tested in SK-MEL-31 human melanoma cells and wild-type AB/TU zebrafish embryos. Ten derivatives inhibited mushroom tyrosinase more potently than kojic acid. Linker length and aromatic substitution strongly influenced activity, with TDP10 and TDP2 showing the highest potency (IC50 = 0.41 and 0.79 μM, respectively). Kinetic studies revealed inhibition profiles consistent with a non-competitive mechanism for both compounds. The selected derivatives reduced α-MSH-induced intracellular tyrosinase activity at 50 μM, with TDP7 producing the greatest effect. In zebrafish embryos, TDP2, TDP7, and TDP10 reduced pigmentation to different extents, with TDP7 showing a marked effect at 100 μM. Developmental toxicity assessment revealed concentration-dependent adverse effects at 100 μM, particularly for TDP10, whereas no adverse endpoints were observed at lower concentrations. These findings identify the thiazolidine-2,4-dione-aryl/benzylpiperazine scaffold as a promising starting point for the development of new tyrosinase inhibitors, while highlighting the importance of further efficacy and safety evaluation.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


